EGFR and lung adenocarcinoma: In our previous experience, the survival curve of Sardinian lung adenocarcinoma patients carrying even very low rates (≤1.5%) of EGFR-T790M variants at baseline was significantly poorer in comparison to that of cases without such a mutation [38].